Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 40Neoplasms 36Prostatic Neoplasms 32Colorectal Neoplasms 22Carcinoma, Non-Small-Cell Lung 22Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Neoplasm Metastasis 14Polycystic Ovary Syndrome 13Lung Neoplasms 13Stomach Neoplasms 12Multiple Myeloma 11Carcinoma, Hepatocellular 11Recurrence 10Pancreatic Neoplasms 10Urinary Bladder Neoplasms 9Lymphoma 9Leukemia 9Myelodysplastic Syndromes 8Motor Activity 8Head and Neck Neoplasms 8Liver Neoplasms 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Esophageal Neoplasms 7Colonic Neoplasms 7Brain Neoplasms 7Pain 6Ovarian Neoplasms 6Lymphoma, Non-Hodgkin 6Lymphoma, Follicular 6

Interventions

Pharmaceutical Preparations 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Completed × Nephrotic Syndrome × Clear all
NCT00035334 2006-02-14

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Bellus Health Inc. - a GSK company

Phase 2/3 Completed
150 enrolled
GastrointestinalGenitourinaryPlasma cell

Amyloidosis, Arthritis, Rheumatoid, Gastrointestinal Diseases, Kidney Diseases, Neoplasm Metastasis, Nephrotic Syndrome, Familial Mediterranean Fever

Data powered by HemOnc (CC BY 4.0) Colophon âš¡